| 1 |
35228653 | CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers. | 2022 Feb 28 |
2 |
| 2 |
33295756 | In Vivo Pretargeting Based on Cysteine-Selective Antibody Modification with IEDDA Bioorthogonal Handles for Click Chemistry. | 2021 Jan 20 |
1 |
| 3 |
34013721 | A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid. | 2021 Jun 16 |
1 |
| 4 |
34232618 | Protein Conjugation by Electrophilic Alkynylation Using 5-(Alkynyl)dibenzothiophenium Triflates. | 2021 Aug 18 |
1 |
| 5 |
34902075 | Self-Assembled Nanomicelles of Affibody-Drug Conjugate with Excellent Therapeutic Property to Cure Ovary and Breast Cancers. | 2021 Dec 13 |
2 |
| 6 |
32931277 | Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach. | 2020 Oct 22 |
1 |
| 7 |
31285754 | Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A. | 2019 |
1 |
| 8 |
31726009 | Development of a Cysteine-Conjugatable Disulfide FRET Probe: Influence of Charge on Linker Cleavage and Payload Trafficking for an Anti-HER2 Antibody Conjugate. | 2019 Dec 18 |
1 |
| 9 |
31930187 | Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation. | 2019 Oct |
1 |
| 10 |
29482952 | Site-selective installation of an electrophilic handle on proteins for bioconjugation. | 2018 Jul 15 |
1 |
| 11 |
29780549 | A thioether-directed palladium-cleavable linker for targeted bioorthogonal drug decaging. | 2018 May 7 |
1 |
| 12 |
27842890 | New small 99mTc-labeled peptides for HER2 receptor imaging. | 2017 Feb 15 |
3 |
| 13 |
27208443 | Surface modification with zwitterionic cysteine betaine for nanoshell-assisted near-infrared plasmonic hyperthermia. | 2016 Sep 1 |
2 |
| 14 |
27426242 | [Mechanism of action and preclinical development of afatinib]. | 2016 Apr |
1 |
| 15 |
27678331 | Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth. | 2016 Dec |
1 |
| 16 |
24454709 | In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. | 2014 |
2 |
| 17 |
24493095 | Cysteine co-oxidation process driven by native peptide folding: an example on HER2 receptor model system. | 2014 May |
1 |
| 18 |
24643470 | A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. | 2014 Jun |
2 |
| 19 |
25070180 | Screening and identification of small molecule inhibitors of ErbB2-induced invasion. | 2014 Dec |
2 |
| 20 |
25282673 | Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re. | 2014 Nov 24 |
1 |
| 21 |
23827065 | [Expression and affinity purification of recombinant human epidermal growth factor receptor-2 affibody with C-terminal cystein]. | 2013 Jun |
1 |
| 22 |
22464443 | ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. | 2012 Mar 30 |
2 |
| 23 |
21147502 | Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. | 2011 Mar |
1 |
| 24 |
21321280 | Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. | 2011 Mar |
1 |
| 25 |
21428412 | Characterization and comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: using LC-MS with electron transfer dissociation. | 2011 Apr 15 |
2 |
| 26 |
21501640 | Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). | 2011 Jul 30 |
3 |
| 27 |
19557480 | Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. | 2010 Jan-Feb |
2 |
| 28 |
20226194 | Design of an optimized scaffold for affibody molecules. | 2010 Apr 30 |
2 |
| 29 |
20610158 | Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. | 2010 Jul |
1 |
| 30 |
19372467 | Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. | 2009 May |
7 |
| 31 |
19642689 | Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. | 2009 Aug 19 |
3 |
| 32 |
19751177 | Comparative binding analysis of monoclonal antibodies against native and mutant type in ErbB2 receptor: a theoretical modeling approach. | 2009 Nov |
1 |
| 33 |
18157531 | [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. | 2008 May |
2 |
| 34 |
18701486 | Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. | 2008 Aug 15 |
1 |
| 35 |
19053310 | Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. | 2008 Dec |
1 |
| 36 |
15173008 | Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. | 2004 Jun 1 |
1 |
| 37 |
20641256 | 177Lu-CHX-A''-DTPA-ABD-Affibody (ZHER2:342)2 | 2004 |
1 |
| 38 |
22896861 | 111In/125I/99mTc-Labeled N-terminus tri-(histidine-glutamate) (HE)3-tagged and N- or C-terminus hexahistidine (H6)-tagged anti-epidermal growth factor receptor Affibody ZHER2:342-C | 2004 |
1 |
| 39 |
22896866 | 18F-Labeled Cys-ZHER2:342, an anti-epidermal growth factor receptor-2 Affibody | 2004 |
4 |
| 40 |
23101053 | QD800-Polyethylene glycol-Cys-ZHER2:342 Affibody | 2004 |
1 |
| 41 |
23193615 | [18F]Fluorobenzoyl anti-HER2 Cys-diabody | 2004 |
8 |
| 42 |
12569553 | Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling. | 2003 Apr 10 |
1 |
| 43 |
9637257 | An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. | 1998 May 15 |
2 |
| 44 |
9710621 | Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. | 1998 Sep |
3 |
| 45 |
9089334 | Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. | 1997 Mar 28 |
2 |
| 46 |
9409448 | MHC-peptide binding: dimers of cysteine-containing nonapeptides bind with high affinity to HLA-A2.1 class I molecules. | 1997 Nov |
1 |
| 47 |
1981143 | The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3. | 1990 Dec |
1 |
| 48 |
3093080 | Alternative 5' exons and tissue-specific expression of the Drosophila EGF receptor homolog transcripts. | 1986 Sep 26 |
1 |